Mutant huntingtin does not affect the intrinsic phenotype of human Huntington's disease T lymphocytes

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Miller, James R C ^a   Träger, Ulrike ^a,b   Andre, Ralph ^a   Tabrizi, Sarah J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; HTT PROTEIN, HUMAN; NERVE PROTEIN;

ADAPTIVE IMMUNITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EX VIVO STUDY; GENETIC TRANSCRIPTION; HELPER CELL; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; MUTANT; PHENOTYPE; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TRANSCRIPTION REGULATION; CELL CULTURE; FEMALE; GENETICS; IMMUNOLOGY; MALE; MUTATION; PATHOLOGY;

ADAPTIVE IMMUNITY; CELLS, CULTURED; FEMALE; HUMANS; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; IMMUNITY, INNATE; MALE; MUTATION; NERVE TISSUE PROTEINS; T-LYMPHOCYTES;

EID: 84951792803     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141793     Document Type: Article

References (33)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993; 72(6):971-83. PMID: 8458085
2. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011; 10(1):83-98. doi: 10.1016/S1474-4422(10)70245-3 PMID: 21163446
3. van der Burg JM, Björkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol. 2009; 8(8):765-74. doi: 10.1016/S1474-4422(09)70178-4 PMID: 19608102
4. Li SH, Schilling G, Young WS, Li XJ, Margolis RL, Stine OC, et al. Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron. 1993; 11(5):985-93. PMID: 8240819
5. Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain. 2007; 130(Pt 7):1759-66. PMID: 17400599
6. Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med. 2008; 205(8):1869-77. doi: 10.1084/jem.20080178 PMID: 18625748
7. Wild E, Magnusson A, Lahiri N, Krus U, Orth M, Tabrizi SJ, et al. Abnormal peripheral chemokine profile in Huntington's disease. PLoS Curr. 2011; 3:RRN1231. doi: 10.1371/currents.RRN1231 PMID: 21826115
8. Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu HQ, et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell. 2011; 145(6):863-74. doi: 10.1016/j.cell.2011.05.020 PMID: 21640374
9. Bouchard J, Truong J, Bouchard K, Dunkelberger D, Desrayaud S, Moussaoui S, et al. Cannabinoid Receptor 2 Signaling in Peripheral Immune Cells Modulates Disease Onset and Severity in Mouse Models of Huntington's Disease. J Neurosci. 2012; 32(50):18259-68. doi: 10.1523/JNEUROSCI.4008-12.2012 PMID: 23238740
10. Träger U, Andre R, Lahiri N, Magnusson-Lind A, Weiss A, Grueninger S, et al. HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation. Brain. 2014; 137(Pt 3):819-33. doi: 10.1093/brain/awt355 PMID: 24459107
11. Kwan W, Träger U, Davalos D, Chou A, Bouchard J, Andre R, et al. Mutant huntingtin impairs immune cell migration in Huntington disease. J Clin Invest. 2012; 122(12):4737-47. doi: 10.1172/JCI64484 PMID: 23160193
12. Träger U, Andre R, Magnusson-Lind A, Miller JR, Connolly C, Weiss A, et al. Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models. Neurobiol Dis. 2014; 73C:388-98.
13. Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol. 2015; 16(4):343-53. doi: 10.1038/ni.3123 PMID: 25789684
14. Shanker A. Adaptive control of innate immunity. Immunol Lett. 2010; 131(2):107-12. doi: 10.1016/j.imlet.2010.04.002 PMID: 20394777
15. +T cells: differentiation and functions. Clin Dev Immunol. 2012; 2012:925135. doi: 10.1155/2012/925135 PMID: 22474485
16. Weiss A, Träger U, Wild EJ, Grueninger S, Farmer R, Landles C, et al. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. J Clin Invest. 2012; 122(10):3731-6. doi: 10.1172/JCI64565 PMID: 22996692
17. Quah BJ, Warren HS, Parish CR. Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat Protoc. 2007; 2(9):2049-56. PMID: 17853860
18. Hawkins ED, Hommel M, Turner ML, Battye FL, Markham JF, Hodgkin PD. Measuring lymphocyte proliferation, survival and differentiation using CFSE time-series data. Nat Protoc. 2007; 2(9):2057-67. PMID: 17853861
19. Roederer M. Interpretation of cellular proliferation data: avoid the panglossian. Cytometry A. 2011; 79(2):95-101. doi: 10.1002/cyto.a.21010 PMID: 21265003
20. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet. 2006; 15(6):965-77. PMID: 16467349
21. Chen-Plotkin AS, Sadri-Vakili G, Yohrling GJ, Braveman MW, Benn CL, Glajch KE, et al. Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease. Neurobiol Dis. 2006; 22(2):233-41. PMID: 16442295
22. Benn CL, Sun T, Sadri-Vakili G, McFarland KN, DiRocco DP, Yohrling GJ, et al. Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. J Neurosci. 2008; 28(42):10720-33. doi: 10.1523/JNEUROSCI.2126-08.2008 PMID: 18923047
23. Silvestroni A, Faull RL, Strand AD, Möller T. Distinct neuroinflammatory profile in post-mortem human Huntington's disease. Neuroreport. 2009; 20(12):1098-103. doi: 10.1097/WNR.0b013e32832e34ee PMID: 19590393
24. Khoshnan A, Ko J, Watkin EE, Paige LA, Reinhart PH, Patterson PH. Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J Neurosci. 2004; 24(37):7999-8008. PMID: 15371500
25. Hayden MS, Ghosh S. NF-κB in immunobiology. Cell Res. 2011; 21(2):223-44. doi: 10.1038/cr.2011.13 PMID: 21243012
26. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol. 2005; 5(6):472-84. PMID: 15928679
27. Dodeller F, Schulze-Koops H. The p38 mitogen-activated protein kinase signaling cascade in CD4 T cells. Arthritis Res Ther. 2006; 8(2):205. PMID: 16542479
28. Okun E, Griffioen KJ, Lathia JD, Tang SC, Mattson MP, Arumugam TV. Toll-like receptors in neurodegeneration. Brain Res Rev. 2009; 59(2):278-92. doi: 10.1016/j.brainresrev.2008.09.001 PMID: 18822314
29. Brownlie RJ, Zamoyska R. T cell receptor signalling networks: branched, diversified and bounded. Nat Rev Immunol. 2013; 13(4):257-69. doi: 10.1038/nri3403 PMID: 23524462
30. González-Navajas JM, Fine S, Law J, Datta SK, Nguyen KP, Yu M, et al. TLR4 signaling in effector CD4+ T cells regulates TCR activation and experimental colitis in mice. J Clin Invest. 2010; 120(2):570-81. doi: 10.1172/JCI40055 PMID: 20051628
31. Kang SM, Tran AC, Grilli M, Lenardo MJ. NF-kappa B subunit regulation in nontransformed CD4+ T lymphocytes. Science. 1992; 256(5062):1452-6.PMID: 1604322
32. Träger U, Magnusson A, Lahiri Swales N, Wild E, North J, Lowdell M, et al. JAK/STAT Signalling in Huntington's Disease Immune Cells. PLoS Curr. 2013; 5.
33. Ellrichmann G, Reick C, Saft C, Linker RA. The role of the immune system in Huntington's disease. Clin Dev Immunol. 2013; 2013:541259. doi: 10.1155/2013/541259 PMID: 23956761